PAVK der unteren Extremitäten – konservative und antithrombotische Therapie

Birgit Linnemann; Martina Schulz; Wilma Schierling; Karin Pfister

doi:10.1055/a-0730-2220

Gefäßmedizin Scan - Zeitschrift für Angiologie, Gefäßchirurgie, diagnostische und interventionelle Radiologie, Inhaltsverzeichnis

Gefäßmedizin Scan - Zeitschrift für Angiologie, Gefäßchirurgie, diagnostische und interventionelle Radiologie 2018; 05(04): 277-293
DOI: 10.1055/a-0730-2220

CME-Fortbildung

PAVK der unteren Extremitäten – konservative und antithrombotische Therapie

Authors

Birgit Linnemann
Martina Schulz
Wilma Schierling
Karin Pfister

Verantwortlicher Herausgeber dieser Rubrik: Wissenschaftlich verantwortlich gemäß Zertifizierungsbestimmungen für diesen Beitrag ist Prof. Dr. med. Birgit Linnemann, Regensburg.

Abstract

Die periphere arterielle Verschlusskrankheit geht mit einem erhöhten Risiko für kardio- und zerebrovaskuläre Komplikationen sowie für die kritische Extremitätenischämie einher. Konservative Therapie kann diese Risiken nachweislich signifikant senken. Trotzdem werden die Patienten oft untertherapiert. Ziel dieser Übersichtsarbeit ist es, die aktuelle Datenlage und Leitlinienempfehlungen zur optimalen konservativen Therapie aufzuzeigen.

Schlüsselwörter

Periphere arterielle Verschlusskrankheit - konservative Therapie - antithrombotische Therapie

Volltext

Referenzen

Referenzen
1 Sigvant B, Lundin F, Wahlberg E. The risk of disease progression in peripheral arterial disease is higher than expected: a meta-analysis of mortality and disease progression in peripheral arterial disease. Eur J Vasc Endovasc Surg 2016; 51: 395-403
2 Malyar N, Freisinger E, Reinecke H. Periphere arterielle Verschlusskrankheit – Entwicklungen zur Morbidität und Letalität in Deutschland. Dtsch Med Wochenschr 2018; 143: 766-770
3 Malyar NM, Freisinger E, Meyborg M. et al. Low rates of revascularization and high in-hospital mortality in patients with ischemic lower limb amputation: morbidity and mortality of ischemic amputation. Angiology 2016; 67: 860-869
4 Aboyans V, Ricco JB, Bartelink ML. et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur Heart J 2018; 39: 763-816
5 Lawall H, Huppert P, Rümenapf G. et al. S3-Leitlinie PAVK – Diagnostik, Therapie und Nachsorge der peripheren arteriellen Verschlusskrankheit. Vasa 2016; 45 (Suppl. 95) 1-100
6 Chen DC, Armstrong EJ, Singh GG. et al. Adherence to guideline-recommended therapies among patients with diverse manifestations of vascular disease. Vasc Health Risk Manag 2015; 11: 185-192
7 Fowkes FG, Rudan D, Rudan I. et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systemic review and analysis. Lancet 2013; 382: 1329-1340
8 Hackshaw A, Morris JK, Boniface S. et al. Low cigarette consumption and risk of coronary heart disease and stroke: meta-analysis of 141 cohort studies in 55 study reports. BMJ 2018; 360: j5855
9 Jha P, Peto R. Global effects of smoking, of quitting and of taxing tobacco. N Engl J Med 2014; 370: 60-68
10 Piepoli MF, Hoes AW, Agewall S. et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 2016; 252: 207-274
11 Lane R, Ellis B, Watson L. et al. Exercise for intermittent claudication. Cochrane Database Syst Rev 2014; 7: CD0009. doi:10.1002/14651858.CD000990.pub3
12 Nordanstieg J, Taft C, Nehsäter M. et al. Improved quality of life after 1 year with an invasive versus a noninvasive treatment strategy in claudicants. One year results oft he invasive revascularization of not in intermittent claudication (IRONIC) trial. Circulation 2014; 130: 939-947
13 Fakhry F, Spronk S, van der Laan L. et al. Endovascular revascularization and supervised exercise for peripheral artery disease and intermittent claudication: a randomized clinical trial. JAMA 2015; 314: 1936-1944
14 Shahin Y, Barnes R, Barakat H. et al. Meta-analysis of angiotensin converting enzyme inhibitors effect on walking ability and ankle brachial pressure index in patients with intermittent claudication. Atherosclerosis 2013; 231: 283-290
15 Iida O, Yokoi H, Soga Y. et al. Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study. Circulation 2013; 127: 2307-2315
16 Berwanger O, Le ManachY, Suzumura EA. et al. Association between pre-operative statin use and major cardiovascular complications among patients undergoing non-cardiac surgery: the VISION study. Eur Heart J 2016; 37: 177-185
17 Arya S, Khakharia A, Zachary OB. et al. Association of statin dose with amputation and survival in patients with peripheral artery disease. Circulation 2018; 137: 1435-1446
18 Laufs U, Scharnagl H, Halle M. et al. Treatment options for statin-associated muscle symptoms. Dtsch Arztebl Int 2015; 112: 748-755
19 Murphy SA, Cannon CP, Blazing MA. et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post-acute coronary syndrome: the IMPROVE-IT Trial. J Am Coll Cardiol 2016; 67: 353-361
20 Bonaca MP, Nault P, Giugliano RP. et al. Low-density lipoprotein cholesterol lowering with evoloumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects with Elevated Risk). Circulation 2018; 137: 338-350
21 Whelton PK, Carey RM, Aronow WS. et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018; 71: e13-e115
22 Mancia G, Fagard R, Narkiewicz K. et al. 2013 ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281-12357
23 Krämer BK, Hausberg M, Sanner B. et al. für die Task Force Wissenschaftliche Stellungnahmen und Leitlinien der DHL: Blutdruckmessung und Zielblutdruck. Dtsch Med Wochenschr 2017; 142: 1446-1447
24 Cushman WC, Whelton PK, Fine LJ. et al. SPRINT trial results: latest news in hypertension management. Hypertension 2016; 67: 263-265
25 Aronow WS, Ahn C. Effect of beta blockers on incidence of new coronary events in older persons with prior myocardial infarction and symptomatic peripheral arterial disease. Am J Cardiol 2001; 87: 1284-1286
26 Mirault TGA, Cambou JP, Lacroix P. et al. Impact of beta-blockers on general and local outcome in patients hospitalized for lower extremity peripheral artery disease. The COPART Registry. Medicine 2017; 96: e5916
27 Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). 1. Aufl. Version 3 Nationale VersorgungsLeitlinie „Therapie des Typ-2-Diabetes“ – Langfassung. Im Internet: zuletzt geändert: April 2014 (Stand: 20.10.2018) http://www.versorgungsleitlinien.de/themen/diabetes2/dm2_therapie
28 Verma S, Mazer CD, Al-Omran M. et al. Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes mellitus and peripheral artery disease: a subanalysis of EMPA-REG OUTCOME. Circulation 2018; 137: 405-407
29 CAPRIE SteeringCommittee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339
30 Hiatt WR, Fowkes FG, Heizer G. et al. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med 2017; 376: 32-40
31 Cacoub PP, Bhatt DL, Steg PG. et al. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J 2009; 30: 192-201
32 Anand SS, Bosch J, Eikelboom JW. et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2018; 391: 219-229
33 van Overhagen H, Spiliopoulos S, Tsetis D. Below-the-knee interventions. Cardiovasc Intervent Radiol 2013; 36: 302-311
34 Katsanos K, Tepe G, Testis D. et al. Standards of practice for superficial femoral and popliteal artery angioplasty and stenting. Cardiovasc Intervent Radiol 2014; 37: 592-603
35 Baumhäkel M, Kindermann M. Praxis der Thrombozyten-Aggregationshemmung nach Katheterintervention der Becken-/Beinarterien in Deutschland. Dtsch Med Wochenschr 2016; 141: e24-e31
36 Tangelder M, Nwachuku CE, Jaff M. et al. A review of antithrombotic therapy and the rationale and design of the Randomized Edoxaban in Patients with Peripheral Artery Disease (ePAD) Trial adding edoxaban or clopidogrel to aspirin after femoropopliteal endovascular intervention. J Endovasc Ther 2015; 22: 261-268
37 Bedenis R, Lethaby A, Maxwell H. et al. Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. Cochrane Database Syst Rev 2015; 2: CD000535. doi:10.1002/14651858.CD000535
38 Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial. Lancet 2000; 355: 346-351
39 Johnson WC, Williford WO. Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study. J Vasc Surg 2002; 35: 413-421
40 Belch JJ, Dormandy J, Biasi GM. et al. Results of the randomized, placebo-controlled Clopidogrel and Acetylsalicylic Acid in Bypass Surgery for Peripheral Arterial Disease (CASPAR) Trial. J Vasc Surg 2010; 52: 825-833
41 Bonaca MP, Bhatt DL, Storey RF. et al. Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease. J Am Coll Cardiol 2016; 67: 2719-2728
42 Franzone A, Piccolo R, Gargiulo G. et al. Prolonged vs short duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with or without peripheral arterial disease: a subgroup analysis of the PRODIGY randomized clinical trial. JAMA Cardiol 2016; 1: 795-803
43 Lamberts M, Lip GY, Ruwald MH. et al. Antithrombotic treatment in patients with heart failure and associated atrial fibrillation and vascular disease: a nationwide cohort study. JACC 2014; 303: 2689-2698
44 Steffel J, Verhamme P, Potpara TS. et al. The 2018 European Heart Rhythm Association practical guides on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. Eur Heart J 2018; 39: 1330-1393